Electronic Design2d
How to Push ADAS Processors Beyond 100 A While Ensuring Functional Safety
Functions ranging from parking assistance to full autonomous driving require multicore processors powered by buck converters ...
X-FAB: A Buy Opportunity Amid Short-Term Volatility
X-FAB Silicon’s SiC revenue decline is temporary, with recovery expected in 2025. See why XFABF stock is a buy with strong ...
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in ...
Fierce Biotech5d
Cassava stops Alzheimer's program as simufilam fails another phase 3
Cassava Sciences has given up on simufilam in Alzheimer’s disease. | Cassava Sciences has given up on simufilam in ...
pharmaphorum4d
End of the line for Cassava's troubled Alzheimer's programme
The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...
Cassava ends simufilam Alzheimer’s programme after second Phase III failure
While investigations into the drug are stopping in Alzheimer’s disease, the therapy is now being evaluated in TSC-related ...
manilatimes6d
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
The co-primary endpoints were the change in cognition and function from baseline to the end of the double-blind treatment period at week 76, assessed by the ADAS-COG12 and ADCS-ADL scales, comparing ...
Adolis García's 2-run double and go-ahead HR leads the Rangers to a 4-3 win over Red Sox
Adolis García put Texas ahead to stay with his first homer of the season after an earlier two-run double and the Rangers beat ...
Cassava Sciences, Inc.: Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's diseaseSimufilam continued to dem ...